For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | - | 405,486* | 1,232,938 | 861,184 |
| Research and development | 2,842,728 | 5,174,239.75* | 2,345,843 | 4,177,054 |
| General and administrative | 1,229,807 | 1,231,330* | 1,023,821 | 945,163 |
| Loss on early termination of vendor agreement | - | -113,283.75* | - | - |
| Total operating expenses | 4,072,535 | 6,518,853.5* | 3,369,664 | 5,122,217 |
| Loss from operations | -4,072,535 | -6,113,367.5* | -2,136,726 | -4,261,033 |
| Grant income | 751,691 | - | - | - |
| Interest income | 132,889 | 195,072.5* | 138,064 | 128,025 |
| Other income | 8,677 | -234,888* | - | 117,444 |
| Loss from operations before income taxes | - | -6,153,183* | - | - |
| Income tax (benefit) expense | - | -3,789* | - | - |
| Net loss | -3,179,278 | -6,149,394 | -1,998,662 | -4,015,564 |
| Basic EPS | -0.16 | -0.402 | -0.12 | -0.29 |
| Diluted EPS | -0.16 | -0.402 | -0.12 | -0.29 |
| Basic Average Shares | 19,314,742 | 15,310,308* | 16,757,678 | 13,956,562 |
| Diluted Average Shares | 19,314,742 | 15,310,308* | 16,757,678 | 13,956,562 |
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)